

# Yannick De Vlaeminck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3296958/publications.pdf>

Version: 2024-02-01

6  
papers

142  
citations

1684188

5  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

212  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177 <sup>66</sup> -Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1136-1148.	4.1	5
2	Emerging applications of nanobodies in cancer therapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , 143-199.	3.2	9
3	Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer. <i>EJNMMI Research</i> , 2021, 11, 115.	2.5	5
4	Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development. <i>Cancers</i> , 2020, 12, 3582.	3.7	23
5	Theranostics in immuno-oncology using nanobody derivatives. <i>Theranostics</i> , 2019, 9, 7772-7791.	10.0	83
6	Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages. <i>Journal of Controlled Release</i> , 2019, 299, 107-120.	9.9	17